Deactivation of alveolar macrophages in septic neutropenic ARDS

被引:31
作者
Mokart, D
Guery, BP
Bouabdallah, R
Martin, C
Blache, JL
Arnoulet, C
Mege, JL
机构
[1] Inst J Paoli I Calmettes, Dept Anesthesiol, F-13273 Marseille 9, France
[2] Inst J Paoli I Calmettes, Intens Care Unit, F-13273 Marseille 9, France
[3] Inst J Paoli I Calmettes, Dept Hematol, F-13273 Marseille 9, France
[4] CH Dron, Dept Crit Care & Infect Dis, Tourcoing, France
[5] Hop Nord Marseille, Dept Anesthesiol, Marseille, France
[6] Hop Nord Marseille, Intens Care Unit, Marseille, France
[7] Hop Conception, Lab Immunol & Hematol, Marseille, France
关键词
alveolar macrophage; ARDS; human leukocyte antigen-DR; neutropenia;
D O I
10.1378/chest.124.2.644
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: Neutrophils often have been involved in the pathophysiology of ARDS. However, authentic ARDS has been described in patients with severe neutropenia, suggesting the presence of other potential mechanisms that are responsible of this syndrome. Alveolar macrophages (AMs) could be involved in the development of ARDS, and so we decided to study AM activation in neutropenic patients. Patients: We designed a prospective study and enrolled two subgroups of consecutive patients (group A, IS patients; group B, 22 patients) with septic ARDS. In the first period, 7 of 18 patients were neutropenic, and in the second period 10 of 22 patients were neutropenic. All neutropenic patients were treated with granulocyte colony-stimulating factor, (G-CSF). Measurements and results: in group A, BAL fluid samples were analyzed for differential and total cell counts, and alveolar activation marker expression (ie, human leukocyte antigen [HLA]-DR locus) was determined. Basal and lipopolysaccharide (LPS)-stimulated production of tumor necrosis factor, interleukin IL-6, and IL-10. was evaluated in group B. In neutropenic patients, the BAL fluid total cell count and the neutrophil absolute count was significantly lower compared to those in nonneutropenic patients (p = 0.029 and p = 0.046, respectively). HLA-DR expression on AMs was significantly decreased (p = 0.016), and the percentage of AMs expressing HLA-DR was also significantly lower (p = 0.041). In neutropenic patients, the mean percentage of AMs expressing HLA-DR was significantly lower in deceased patients compared to survivors (30 +/- 7 vs 43 +/- 1, respectively; p = 0.047). Basal AMs released cytokines was comparable between the two groups; however, LPS stimulation yielded a deactivation of AMs in neutropenic patients. Conclusion: These results suggest a deactivation and/or hypoactivation of AMs in septic ARDS patients. This deactivation/hypoactivation could be linked to the use of G-CSF as this molecule has been shown to generate a down-regulation of HLA-DR expression.
引用
收藏
页码:644 / 652
页数:9
相关论文
共 51 条
[1]  
Alberts W. Michael, 1997, Current Opinion in Oncology, V9, P161
[2]  
Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO
[3]  
2-4
[4]   Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo [J].
Aman, MJ ;
Stockdreher, K ;
Thews, A ;
Kienast, K ;
Aulitzky, WE ;
Farber, L ;
Haus, U ;
Koci, B ;
Huber, C ;
Peschel, C .
ANNALS OF HEMATOLOGY, 1996, 73 (05) :231-238
[5]  
ASHBAUGH DG, 1967, LANCET, V2, P319
[6]   Changes in the inflammatory response of the lung during acute respiratory distress syndrome: Prognostic indicators [J].
Baughman, RP ;
Gunther, KL ;
Rashkin, MC ;
Keeton, DA ;
Pattishall, EN .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (01) :76-81
[7]   THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ARDS - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES, AND CLINICAL-TRIAL COORDINATION [J].
BERNARD, GR ;
ARTIGAS, A ;
BRIGHAM, KL ;
CARLET, J ;
FALKE, K ;
HUDSON, L ;
LAMY, M ;
LEGALL, JR ;
MORRIS, A ;
SPRAGG, R ;
COCHIN, B ;
LANKEN, PN ;
LEEPER, KV ;
MARINI, J ;
MURRAY, JF ;
OPPENHEIMER, L ;
PESENTI, A ;
REID, L ;
RINALDO, J ;
VILLAR, J ;
VANASBECK, BS ;
DHAINAUT, JF ;
MANCEBO, J ;
MATTHAY, M ;
MEYRICK, B ;
PAYEN, D ;
PERRET, C ;
FOWLER, AA ;
SCHALLER, MD ;
HUDSON, LD ;
HYERS, T ;
KNAUS, W ;
MATTHAY, R ;
PINSKY, M ;
BONE, RC ;
BOSKEN, C ;
JOHANSON, WG ;
LEWANDOWSKI, K ;
REPINE, J ;
RODRIGUEZROISIN, R ;
ROUSSOS, C ;
ANTONELLI, MA ;
BELOUCIF, S ;
BIHARI, D ;
BURCHARDI, H ;
LEMAIRE, F ;
MONTRAVERS, P ;
PETTY, TL ;
ROBOTHAM, J ;
ZAPOL, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (03) :818-824
[8]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[9]   Induction of tolerance in macrophages by cholera toxin B chain [J].
Burkart, V ;
Kim, YE ;
Kauer, M ;
Kolb, H .
PATHOBIOLOGY, 1999, 67 (5-6) :314-317
[10]   PHORBOL-MYRISTATE ACETATE PRODUCES INJURY TO ISOLATED RAT LUNGS IN THE PRESENCE AND ABSENCE OF PERFUSED NEUTROPHILS [J].
CARPENTER, LJ ;
JOHNSON, KJ ;
KUNKEL, RG ;
ROTH, RA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 91 (01) :22-32